NCT00073879View on ClinicalTrials.gov

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

NACompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2003

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

graft-versus-tumor induction therapy

DRUG

cyclophosphamide

DRUG

fludarabine phosphate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT00073879 - Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter